glp-1 patients + EMFACE before & after ✨ Weight loss with GLP-1 medications can be life-changing… but it can also come with unexpected facial changes like volume loss, skin laxity, and that “tired” Frontiers | GLP−1 receptor agonists

Incretin therapies: highlighting common features and differences in the modes of action of glucagonlike peptide1 receptor agonists and dipeptidyl peptidase4 inhibitors

However, its crucial to conduct more clinical studies to validate this potential across diverse patient groups, including emulation trials that can evaluate the effect of GLP-1 (receptor agonists) in different subgroups of the population usually not included in large trials, Hung said

The GSH-responsive AP probe-net blocks the APE1 activity, thereby inducing cell death

Nobody with inflammatory bowel disease should reduce or discontinue biologics, immunomodulators or 5-aminosalicylates on the theory that a GLP-1 drug is covering them

doi: 10.3389/fphys.2025.1497566 Received 17 September 2024 Accepted 22 January 2025 Published 10 February 2025 Volume 16 - 2025 Edited by Hongxiang Hui, Monterey Park, United States Reviewed by Phiwayinkosi V